Last edition
News about "Squamous Cell Carcinoma of the Anal Canal"
MHRA Approves Retifanlimab for Advanced Anal Canal Cancer
MHRA approves Incyte's retifanlimab in combination with chemotherapy for adults with unresectable, metastatic or locally recurrent squamous cell carcinoma of the anal canal.
Squamous Cell Carcinoma Of The Anal Canal | 13/11/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members